Webb27 mars 2024 · Recro Pharma, Inc. (NASDAQ:REPH) issued its quarterly earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return … Webb1 mars 2024 · Societal CDMO, Inc. a annoncé qu'elle avait signé des extensions d'ordre de travail avec plusieurs clients existants qui couvrent une variété de domaines d'expertise des services CDMO de la ...

Recro Pharma : Unaudited Pro Forma Combined Statements of …

WebbWHEREAS, Alkermes and Recro Pharma, Inc. entered into that certain Development, Manufacturing and Supply Agreement on July 10, 2015, as amended by that certain First Amendment to the Development, Manufacturing and Supply Agreement between Alkermes and Recro Pharma, Inc. dated as of October 19, 2016 and by that certain Second … WebbRecro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The … garden house cottered buntingford sg9 9pz

David Enloe - President and CEO - Societal™ CDMO

WebbRecro Pharma has raised a total of $226.5M in funding over 5 rounds. Their latest funding was raised on May 12, 2024 from a Post-IPO Equity round. Recro Pharma is registered … WebbRecro Pharma rebrands itself as Societal CDMO in wake of Irisys purchase Fierce Pharma. Fierce Pharma. Fierce Biotech. Fierce Healthcare. Fierce Life Sciences Events. … Webb15 mars 2024 · The corporate mailing address for Mr. Enloe, Jr. and other Recro Pharma executives is 490 LAPP ROAD, MALVERN PA, 19355. Recro Pharma can also be reached via phone at (770) 534-8239 and via email at [email protected]. Has J. David Enloe, Jr. been buying or selling shares of Recro Pharma? black oil sunflower planting